查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1630942

自體細胞治療市場規模、佔有率、趨勢分析報告：按治療類型、治療領域、地區、細分預測，2025-2030 年

Autologous Cell Therapy Market Size, Share & Trends Analysis Report By Therapy Type ( Autologous Therapies, Non-Stem Cell Therapies, Non-Stem Cell Therapies), By Therapeutic Area (Oncology, Dermatology), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10個工作天內

價格

自體細胞治療市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，全球自體細胞治療市場規模預計到2030年將達到182.3億美元，2025年至2030年複合年成長率為22.01%。

癌症、神經退化性疾病疾病、自體免疫疾病、自體免疫疾病和整形外科等疾病和殘疾負擔的增加是推動市場需求的因素。同樣，由於這些治療方法是從患者來源的細胞開發而來的，有助於再生體內受損的組織，因此降低自體細胞療法排斥的風險是市場發展的關鍵驅動力。

在 COVID-19 疫情期間，市場面臨各種挑戰，患者出於安全考慮被迫待在家中。影響市場成長的因素包括製造障礙和醫院病患流入量的減少。然而，在新冠疫情之後，隨著 FDA 批准的多種治療手段取得新進展，市場需求也有所增加。

2020 年 4 月，臨床階段生物技術公司 Hope Biosciences 宣布了 HB-adMSCs（Hope Bioscience 的自體脂肪間質間質幹細胞）在提供對COVID-19 的免疫支持方面的有效性和安全性。了II期臨床試驗評估2020年6月，凱西集團與Holoclar轉讓公司達成協議。 Holoclar 是一種針對眼表燒傷患者的自體幹細胞治療方法。該交易將使兩家公司專注於各自的策略目標，即加速獲得罕見疾病的治療方法。

自體細胞治療市場報告重點

  • 2024 年非幹細胞治療領域佔據市場主導地位，佔有率為 97.41%。這一巨大佔有率歸因於多種因素，包括 CAR-T 細胞療法研究的擴大和臨床試驗的增加。
  • 預計腫瘤學領域將在 2024 年佔據 88.55% 的市場佔有率。 CD19 針對 CAR T 細胞可幫助治療急性淋巴性白血病(ALL) 患者，並達到高完全緩解率和長期緩解率。
  • 2024年北美自體細胞治療市場佔有57.88%的佔有率。由於 BrainStorm Cell Therapeutics 和 Bristol Myers Squibb 等大多數大公司都在該地區開展業務，因此市場競爭非常激烈。
  • 預計預測期內亞太地區自體細胞治療市場將大幅成長。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章自體細胞治療市場變數、趨勢與範圍

  • 市場展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 自體細胞治療市場分析工具
    • 產業分析-波特五力分析
    • PESTEL 分析
    • 管道分析
    • COVID-19影響分析

第4章 治療類型業務分析

  • 全球自體細胞治療市場：治療類型細分儀表板
  • 全球自體細胞治療市場：治療類型變化分析
  • 按治療類型
  • 幹細胞治療
    • 2018 年至 2030 年幹細胞治療市場估計與預測
    • 骨髓、血液和臍帶來源的幹細胞
    • 脂肪來源細胞
    • 其他
  • 非幹細胞療法
    • 2018 年至 2030 年非幹細胞療法市場估計與預測
    • T細胞治療
    • 其他

第5章 治療領域業務分析

  • 全球自體細胞治療市場：治療領域儀表板
  • 全球自體細胞治療市場：治療領域變遷分析
  • 按治療領域分類的收益
  • 腫瘤學
    • 2018 年至 2030 年腫瘤學市場估計與預測
  • 心血管疾病
    • 2018 年至 2030 年心血管疾病市場估計與預測
  • 肌肉骨骼疾病
    • 肌肉骨骼疾病市場估計與預測 2018-2030
  • 皮膚科
    • 2018 年至 2030 年皮膚科市場估計與預測
  • 其他
    • 2018-2030 年其他市場估計與預測
    • 2018-2030 年其他市場估計與預測

第6章 區域經營分析

  • 區域控制面板
  • 市場規模、預測趨勢分析，2018-2030 年：
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 瑞士
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
  • 世界其他地區
    • 2018 年至 2030 年世界其他地區市場估計與預測

第7章 競爭格局

  • 公司分類
  • 2024 年主要企業定位分析
  • 公司簡介/上市公司
    • Bluebird bio, Inc.
    • Novartis AG.
    • Holostem SRL
    • Pharmicell Co. Inc
    • Gilead Sciences, Inc.（Kite）
    • Bristol Myers Squibb Company
    • Johnson &Johnson（Janssen Global Services, LLC.）
    • JW Therapeutics
    • Vertex Pharamaceuticals Inc.
    • Autolus therapeutics
Product Code: GVR-4-68040-017-2

Autologous Cell Therapy Market Growth & Trends:

The global autologous cell therapy market size is expected to reach USD 18.23 billion by 2030, registering a CAGR of 22.01% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growing burden of diseases and disorders such as cancer, neurodegenerative disorders, cardiovascular disorders, autoimmune disorders, and orthopedics are the factors driving the demand for the market. Likewise, the reduced risk of autologous cell therapy rejection is one of the important factors for market growth as these therapies are developed from patient-derived cells and support the regeneration of the damaged tissues in the body.

During the COVID-19 pandemic, the market has witnessed various challenges where patients were restricted to stay at home due to safety concerns. Some factors that affected the market growth are manufacturing hurdles and reduced patient inflow in hospitals. However, post-COVID-19 the market has witnessed the demand for the market with FDA clearance and all of the new advances in treating a wide range of disease indications.

In April 2020, Hope Biosciences, a clinical-stage biotechnology company announced the FDA clearance for a phase II clinical trial evaluating the efficacy & safety of HB-adMSCs (Hope Bioscience' autologous, adipose-derived mesenchymal stem cells), to offer immune support against COVID-19. In June 2020, Chiesi Group and Holostem Terapie Avanzate mentioned the agreement for the transfer of the business branch Holoclar. The Holoclar is an autologous stem cell therapy for patients with ocular surface burns. It aims to allow both companies to focus on the strategic objective and accelerate procedures access for rare diseases.

Autologous Cell Therapy Market Report Highlights:

  • The non-stem cell therapies segment dominated the market in 2024 with a 97.41% share. This large share can be attributed to several factors, including the expanding CAR T-cell therapy research landscape and increasing clinical trials.
  • The oncology segment dominated the market in 2024 with an 88.55% share. CAR T-cells targeting CD19 can help treat Acute Lymphocytic Leukemia (ALL) patients with high rates of full and long-term remission.
  • The North America autologous cell therapy market accounted for 57.88% share in 2024. The market is highly competitive since most major players operate in this region, such as BrainStorm Cell Therapeutics and Bristol Myers Squibb.
  • Asia Pacific's autologous cell therapy market is anticipated to grow significantly over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Therapeutic Area
    • 1.2.2. Therapy Type
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Autologous Cell Therapy Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising prevalence of chronic and degenerative diseases
      • 3.2.1.2. Reduced risk of autologous cell therapy rejection
      • 3.2.1.3. Growing demand for personalized medicine
      • 3.2.1.4. Increasing investments in research & development
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of therapy and limited affordability
      • 3.2.2.2. Stringent regulatory requirements and long approval timelines
  • 3.3. Autologous Cell Therapy Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. COVID-19 Impact Analysis

Chapter 4. Therapy Type Business Analysis

  • 4.1. Global Autologous Cell Therapy Market: Therapy Type Segment Dashboard
  • 4.2. Global Autologous Cell Therapy Market: Therapy Type Movement Analysis
  • 4.3. Global Autologous Cell Therapy Market Estimates and Forecasts, By Therapy Type (USD Million)
  • 4.4. Stem Cell Therapies
    • 4.4.1. Stem cell therapies market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. BM, Blood, & Umbilical Cord-derived Stem Cells
      • 4.4.2.1. BM, blood, & umbilical cord-derived stem cells market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Adipose-Derived Cells
      • 4.4.3.1. Adipose-Derived Cells market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Non-stem Cell Therapies
    • 4.5.1. Non-stem cell therapies market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2. T-Cell Therapies
      • 4.5.2.1. T-Cell Therapies market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.2.2. CAR T Cell Therapy
        • 4.5.2.2.1. CAR T cell therapy market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.2.3. T Cell Receptor (TCR)-based
        • 4.5.2.3.1. T Cell Receptor (TCR)-based market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3. Others
      • 4.5.3.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Therapeutic Area Business Analysis

  • 5.1. Global Autologous Cell Therapy Market: Therapeutic Area Dashboard
  • 5.2. Global Autologous Cell Therapy Market: Therapeutic Area Movement Analysis
  • 5.3. Global Autologous Cell Therapy Market Estimates and Forecasts, By Therapeutic Area, Revenue (USD Million)
  • 5.4. Oncology
    • 5.4.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Cardiovascular Diseases
    • 5.5.1. Cardiovascular diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Musculoskeletal Disorders
    • 5.6.1. Musculoskeletal disorders market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Dermatology
    • 5.7.1. Dermatology market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.8.2. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Regional Business Analysis

  • 6.1. Regional Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. Target disease prevalence
      • 6.3.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Target disease prevalence
      • 6.3.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. Target disease prevalence
      • 6.4.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Target disease prevalence
      • 6.4.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Switzerland
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. Target disease prevalence
      • 6.4.3.5. Switzerland market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Target disease prevalence
      • 6.5.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Target disease prevalence
      • 6.5.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Target disease prevalence
      • 6.5.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. South Korea
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Target disease prevalence
      • 6.5.4.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Rest of the World
    • 6.6.1. Rest of the world market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Key Company Position Analysis, 2024
  • 7.3. Company Profiles/Listing
    • 7.3.1. Bluebird bio, Inc.
      • 7.3.1.1. Company overview
      • 7.3.1.2. Financial performance
      • 7.3.1.3. Product benchmarking
      • 7.3.1.4. Strategic initiatives
    • 7.3.2. Novartis AG.
      • 7.3.2.1. Company overview
      • 7.3.2.2. Financial performance
      • 7.3.2.3. Product benchmarking
      • 7.3.2.4. Strategic initiatives
    • 7.3.3. Holostem S.R.L
      • 7.3.3.1. Company overview
      • 7.3.3.2. Financial performance
      • 7.3.3.3. Product benchmarking
      • 7.3.3.4. Strategic initiatives
    • 7.3.4. Pharmicell Co. Inc
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Gilead Sciences, Inc. (Kite)
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Bristol Myers Squibb Company
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Johnson & Johnson (Janssen Global Services, LLC.)
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. JW Therapeutics
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Vertex Pharamaceuticals Inc.
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Autolus therapeutics
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 Global Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
  • Table 3 Global Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 4 Global Autologous Cell Therapy Market By Region, 2018 - 2030 (USD Million)
  • Table 5 North America Autologous Cell Therapy Market By Country, 2018 - 2030 (USD Million)
  • Table 6 North America Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
  • Table 7 North America Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 8 U.S. Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
  • Table 9 U.S. Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 10 Canada Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
  • Table 11 Canada Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 12 Europe Autologous Cell Therapy Market By Country, 2018 - 2030 (USD Million)
  • Table 13 Europe Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
  • Table 14 Europe Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 15 Germany Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
  • Table 16 Germany Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 17 UK Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
  • Table 18 UK Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 19 Switzerland Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
  • Table 20 Switzerland Autologous Cell Therapy MarketBy Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 21 Asia Pacific Autologous Cell Therapy Market By Country, 2018 - 2030 (USD Million)
  • Table 22 Asia Pacific Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
  • Table 23 Asia Pacific Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 24 China Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
  • Table 25 China Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 26 Japan Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
  • Table 27 Japan Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 28 India Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
  • Table 29 India Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 30 South Korea Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
  • Table 31 South Korea Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)
  • Table 32 Rest Of The World Autologous Cell Therapy Market By Therapy Type, 2018 - 2030 (USD Million)
  • Table 33 Rest Of The World Autologous Cell Therapy Market By Therapeutic Area, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Autologous Cell Therapy Market, Market Segmentation
  • Fig. 7 Market Driver Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Analysis (Current & Future Impact)
  • Fig. 9 PESTEL Analysis
  • Fig. 10 Porter's Five Forces Analysis
  • Fig. 11 Global Autologous Cell Therapy Market: Therapy Type Key Takeaways
  • Fig. 12 Global Autologous Cell Therapy Market: Therapy Type Movement Analysis
  • Fig. 13 Global Autologous Cell Therapy Market For Autologous Stem-Cell Therapies, 2018 - 2030 (USD Million)
  • Fig. 14 Global Autologous Cell Therapy Market For BM, Blood, & Umbilical Cord-Derived Stem Cell Therapies, 2018 - 2030 (USD Million)
  • Fig. 15 Global Autologous Cell Therapy Market For Adipose Derived Cells, 2018 - 2030 (USD Million)
  • Fig. 16 Global Autologous Cell Therapy Market For Others, 2018 - 2030 (USD Million)
  • Fig. 17 Global Autologous Cell Therapy Market For Autologous Non-Stem Cell Therapies, 2018 - 2030 (USD Million)
  • Fig. 18 Global Autologous Cell Therapy Market For T-Cell Therapies, 2018 - 2030 (USD Million)
  • Fig. 19 Global Autologous Cell Therapy Market For CAR T Cell Therapy, 2018 - 2030 (USD Million)
  • Fig. 20 Global Autologous Cell Therapy Market For T Cell Receptor (TCR)-Based, 2018 - 2030 (USD Million)
  • Fig. 21 Global Autologous Cell Therapy Market For Other Autologous Non Stem-Cell Therapies, 2018 - 2030 (USD Million)
  • Fig. 22 Global Autologous Cell Therapy Market: Therapeutic Area Key Takeaways
  • Fig. 23 Global Autologous Cell Therapy Market: Therapeutic Area Movement Analysis
  • Fig. 24 Global Autologous Cell Therapy Market For Oncology, 2018 - 2030 (USD Million)
  • Fig. 25 Global Autologous Cell Therapy Market For Cardiovascular Disease (CVD), 2018 - 2030 (USD Million)
  • Fig. 26 Global Autologous Cell Therapy Market For Musculoskeletal Disorders, 2018 - 2030 (USD Million)
  • Fig. 27 Global Autologous Cell Therapy Market For Dermatology, 2018 - 2030 (USD Million)
  • Fig. 28 Global Autologous Cell Therapy Market For Others, 2018 - 2030 (USD Million)
  • Fig. 29 Regional Outlook, 2024 & 2030
  • Fig. 30 North America Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 31 U.S.Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 32 Canada Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 33 Europe Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 34 Germany Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 35 UK Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 36 Switzerland Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 37 Asia Pacific Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 38 Japan Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 39 China Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 40 India Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 41 South Korea Autologous Cell Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 42 Rest Of The World Autologous Cell Therapy Market, 2018 - 2030 (USD Million)